Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Entecavir“
Suchtreffer
Begriffe & Kennungen
Entecavir Viatris (previously Entecavir Mylan) · 4.8 · Experience in patients with decompensated liver disease: the safety profile of entecavir in patients with deco
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Gastrointestinal disorders: common: vomiting, diarrhoea, nausea, dyspepsia
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Gender/age There was no apparent difference in the safety profile of entecavir with respect to gender (≈ 25% w
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · General disorders and administration site conditions: common: fatigue
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Hepatobiliary disorders: common: increased transaminases
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · In clinical trials in patients with compensated liver disease, the most common adverse reactions of any severi
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · In clinical trials with lamivudine-refractory patients, 4% had ALT elevations >3 times baseline, and <1% had A
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Laboratory test abnormalities In clinical trials with nucleoside-naive patients, 5% had ALT elevations >3 time
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disea
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Nervous system disorders: common: headache, dizziness, somnolence
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Other special populations
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Paediatric population
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Psychiatric disorders: common: insomnia
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Skin and subcutaneous tissue disorders: uncommon: rash, alopecia
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Summary of the safety profile
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · The safety of entecavir in paediatric patients from 2 to <18 years of age is based on two clinical trials in s
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Treatment beyond 48 weeks: continued treatment with entecavir for a median duration of 96 weeks did not reveal
Eintrag öffnenJuluca · 4.5 · Entecavir/ Rilpivirine Rilpivirine (Not studied) Daclatasvir/ Dolutegravir No dose adjustment is required.
Eintrag öffnen